RALLYBIO CORPORATION Increase (Decrease) in Accrued Liabilities
RALLYBIO CORPORATION (RLYB) reported Increase (Decrease) in Accrued Liabilities of -$1.23 million for the 6-month period ending 2026-06-30, per its S-4/A filed 2026-08-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-26
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was -$521.00K, a 132.12% decline year-over-year.
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$712.00K.
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $33.00K.
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was -$350.00K.
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for fiscal 2023 was -$1.44M, a 144.79% decline from fiscal 2022.
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for fiscal 2022 was $3.22M, a 89.08% increase from fiscal 2021.
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for fiscal 2021 was $1.70M, a 76.95% increase from fiscal 2020.
- RALLYBIO CORPORATION increase (decrease) in accrued liabilities for fiscal 2020 was $963.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$521.00K derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | -$1.23M S-4/A · filed 2026-08-26 | -$1.20M derived: sum of 3 quarters · filed 2026-08-26 | -$1.55M derived: sum of 4 quarters · filed 2026-08-26 |
| 2026-03-31 | -$712.00K S-4 · filed 2026-07-15 | -$679.00K derived: sum of 2 quarters · filed 2026-08-26 | -$1.03M derived: sum of 3 quarters · filed 2026-08-26 | $593.00K derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-12-31 | $33.00K derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$317.00K derived: sum of 2 quarters · filed 2026-08-26 | $1.30M derived: sum of 3 quarters · filed 2026-08-26 | -$1.15M S-4/A · filed 2026-08-26 |
| 2025-09-30 | -$350.00K derived: 10-Q 9 month − S-4/A 6 month · filed 2025-11-06 | $1.27M derived: sum of 2 quarters · filed 2026-08-26 | -$1.18M 10-Q · filed 2025-11-06 | -$2.58M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-06-30 | $1.62M derived: S-4/A 6 month − S-4 3 month · filed 2026-08-26 | -$832.00K S-4/A · filed 2026-08-26 | -$2.23M derived: sum of 3 quarters · filed 2026-08-26 | -$5.50M derived: sum of 4 quarters · filed 2026-08-26 |
| 2025-03-31 | -$2.45M S-4 · filed 2026-07-15 | -$3.85M derived: sum of 2 quarters · filed 2026-08-26 | -$7.13M derived: sum of 3 quarters · filed 2026-08-26 | -$7.07M derived: sum of 4 quarters · filed 2026-08-26 |
| 2024-12-31 | -$1.39M derived: S-4/A 12 month − 10-Q 9 month · filed 2026-08-26 | -$4.67M derived: sum of 2 quarters · filed 2026-08-26 | -$4.62M derived: sum of 3 quarters · filed 2026-08-26 | -$3.34M S-4/A · filed 2026-08-26 |
| 2024-09-30 | -$3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.22M derived: sum of 2 quarters · filed 2025-11-06 | -$1.95M 10-Q · filed 2025-11-06 | -$2.64M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $1.33M 10-Q · filed 2025-08-07 | $641.00K derived: sum of 3 quarters · filed 2025-08-07 | $2.16M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $1.27M 10-Q · filed 2025-05-08 | $585.00K derived: sum of 2 quarters · filed 2025-05-08 | $2.10M derived: sum of 3 quarters · filed 2025-05-08 | $3.39M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$687.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $831.00K derived: sum of 2 quarters · filed 2025-03-13 | $2.12M derived: sum of 3 quarters · filed 2025-03-13 | -$1.44M 10-K · filed 2025-03-13 |
| 2023-09-30 | $1.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.81M derived: sum of 2 quarters · filed 2024-11-07 | -$756.00K 10-Q · filed 2024-11-07 | -$1.60M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.27M 10-Q · filed 2024-08-08 | -$3.12M derived: sum of 3 quarters · filed 2024-08-08 | $491.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$3.56M 10-Q · filed 2024-05-09 | -$4.41M derived: sum of 2 quarters · filed 2024-05-09 | -$799.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.07M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$841.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $2.77M derived: sum of 2 quarters · filed 2024-03-12 | $4.63M derived: sum of 3 quarters · filed 2024-03-12 | $3.22M 10-K · filed 2024-03-12 |
| 2022-09-30 | $3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.47M derived: sum of 2 quarters · filed 2023-11-09 | $4.06M 10-Q · filed 2023-11-09 | $5.29M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $457.00K 10-Q · filed 2023-08-08 | $1.69M derived: sum of 3 quarters · filed 2023-08-08 | $3.13M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$1.41M 10-Q · filed 2023-05-09 | -$176.00K derived: sum of 2 quarters · filed 2023-05-09 | $1.27M derived: sum of 3 quarters · filed 2023-05-09 | $1.47M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.67M derived: sum of 2 quarters · filed 2023-03-06 | $2.88M derived: sum of 3 quarters · filed 2023-03-06 | $1.70M 10-K · filed 2023-03-06 |
| 2021-09-30 | $1.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $1.64M derived: sum of 2 quarters · filed 2022-11-07 | $472.00K 10-Q · filed 2022-11-07 | $1.63M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$970.00K 10-Q · filed 2022-08-08 | $184.00K derived: sum of 3 quarters · filed 2022-08-08 | -$45.00K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | -$1.17M 10-Q · filed 2022-05-10 | -$18.00K derived: sum of 2 quarters · filed 2022-05-10 | -$247.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $925.00K derived: sum of 2 quarters · filed 2022-03-15 | $963.00K 10-K · filed 2022-03-15 | |
| 2020-09-30 | -$229.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$191.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $38.00K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |